The druggable genome
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
An assessment of the number of molecular targets that represent an opportunity for therapeutic intervention is crucial to the development of post-genomic research strategies within the pharmaceutical industry. Now that we know the size of the human genome, it is interesting to consider just how many molecular targets this opportunity represents. We start from the position that we understand the properties that are required for a good drug, and therefore must be able to understand what makes a good drug target.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The dataset adds high-quality structural models across a broad range of Gene Ontology (GO) terms36,37, including pharmaceutically relevant classes such as enzymes and membrane proteins38 (Fig. 1d).”
From Highly accurate protein structure prediction for the human proteome (2021) · cites this paper as [38]
In the citing paper
“Proteins have several additional advantages as they are most often the direct mediators of biological processes and form the vast majority of currently druggable targets in disease160.”
From Measuring biological age using omics data (2022) · cites this paper as [160]
In the citing paper
“Only around 20% of the human proteome is considered to be druggable with small-molecule antagonists.”
From Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence (2023) · cites this paper as [2]
In the citing paper
“Although this has been a highly effective approach, it has left potential drug targets undrugged or underdrugged45.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [45]
Citations
Cites
Initial sequencing and analysis of the human genome
International Human Genome Sequencing Consortium, Whitehead Institute for Biomedical Research, C. F. G. R., Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., et al. (2001) · Nature · doi:10.1038/35057062 · Cited by 24,216
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
The sequence of the human genome
Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., Smith, H. O., Yandell, M., Evans, C. A., Holt, R. A., et al. (2001) · Science · doi:10.1126/science.1058040 · Cited by 13,909
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Drug Discovery: A Historical Perspective
Drews, J. (2000) · Science · doi:10.1126/science.287.5460.1960 · Cited by 2,760 · cited 1×
“identified 483 targets, and concluded that there could be 5,000–10,000 potential targets on the basis of an estimate of the number of disease-related gene”
BackgroundMetabolite profiling for plant functional genomics
Fiehn, O., Kopka, J., Dörmann, P., Altmann, T., Trethewey, R. N., & Willmitzer, L. (2000) · Nature Biotechnology · doi:10.1038/81137 · Cited by 2,127 · cited 1×
“One route to target discovery might therefore lie in identifying enzymes and receptors from metabolomic profilin”
BackgroundComparative Genomics of the Eukaryotes
Rubin, G. M., Yandell, M. D., Wortman, J. R., Gabor, G. L., Miklos, Nelson, C. R., Hariharan, I. K., Fortini, M. E., Li, P. W., Apweiler, R., et al. (2000) · Science · doi:10.1126/science.287.5461.2204 · Cited by 1,698
Apweiler, R. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.1.37 · Cited by 1,079
A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations
Raamsdonk, L. M., Teusink, B., Broadhurst, D., Zhang, N., Hayes, A., Walsh, M. C., Berden, J. A., Brindle, K. M., Kell, D. B., Rowland, J. J., et al. (2001) · Nature Biotechnology · doi:10.1038/83496 · Cited by 1,005 · cited 1×
“One route to target discovery might therefore lie in identifying enzymes and receptors from metabolomic profilin”
BackgroundTweeddale, H., Notley-McRobb, L., & Ferenci, T. (1998) · Journal of Bacteriology · doi:10.1128/jb.180.19.5109-5116.1998 · Cited by 393 · cited 1×
“One route to target discovery might therefore lie in identifying enzymes and receptors from metabolomic profilin”
Background
Cited by
Items 201–300 of 1,029
Vega, F. M. D. L., Lazaruk, K. D., Rhodes, M. D., & Wenz, M. H. (2005) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2005.01.008 · Cited by 247
Takebe, T., Imai, R., & Ono, S. (2018) · Clinical and Translational Science · doi:10.1111/cts.12577 · Cited by 238
Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis
Sacchettini, J. C., Rubin, E. J., & Freundlich, J. S. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1816 · Cited by 256
“Ideal TB drug targets should have three characteristics: they should be required for bacterial growth and persistence (that is, they must be expressed and essential during the time that treatment occurs); it should be possible to inhibit their activity using small molecules (that is, the target should be 'druggable'”
BackgroundVinayagam, A., Gibson, T. E., Lee, H.-J., Yilmazel, B., Roesel, C., Hu, Y., Kwon, Y., Sharma, A., Liu, Y.-Y., Perrimon, N., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1603992113 · Cited by 257
“Extending the analysis to the list of proteins that are annotated as druggable (32), i.”
BackgroundSystems approaches to polypharmacology and drug discovery.
Boran, A. D. W., & Iyengar, R. (2010) · PubMed · Cited by 343
Functional genomics identifies therapeutic targets for MYC-driven cancer
Toyoshima, M., Howie, H. L., Imakura, M., Walsh, R. M., Annis, J. E., Chang, A. N., Frazier, J., Chau, B. N., Loboda, A., Linsley, P. S., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121119109 · Cited by 242
“The tTS-expressing cells were subsequently infected with an shRNA-expressing lentiviral vector derived frompLenti6 as described (9); shRNA and a scramble were designed and constructed in the pLenti6-tts system using the Gateway LR Clonase.”
BackgroundMethodPredicting Drug-Target Interactions for New Drug Compounds Using a Weighted Nearest Neighbor Profile
van Laarhoven, T., & Marchiori, E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066952 · Cited by 246
“Drug-target interaction data are available for various classes of pharmaceutically useful target proteins including enzymes, ion channels, GPCRs and nuclear receptors [5].”
BackgroundLabel-free measuring and mapping of binding kinetics of membrane proteins in single living cells
Wang, W., Yang, Y., Wang, S., Nagaraj, V. J., Liu, Q., Wu, J., & Tao, N. (2012) · Nature Chemistry · doi:10.1038/nchem.1434 · Cited by 247
Improving the odds of drug development success through human genomics: modelling study
Hingorani, A. D., Kuan, V., Finan, C., Kruger, F. A., Gaulton, A., Chopade, S., Sofat, R., MacAllister, R. J., Overington, J. P., Hemingway, H., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-54849-w · Cited by 247
Design and Structure of Stapled Peptides Binding to Estrogen Receptors
Phillips, C., Roberts, L. R., Schade, M., Bazin, R., Bent, A., Davies, N. L., Moore, R., Pannifer, A. D., Pickford, A. R., Prior, S. H., et al. (2011) · Journal of the American Chemical Society · doi:10.1021/ja202946k · Cited by 247
Critical review of the role of HTS in drug discovery
Macarron, R. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.02.001 · Cited by 241
In Vitro Selection of Highly Modified Cyclic Peptides That Act as Tight Binding Inhibitors
Guillen Schlippe, Y. V., Hartman, M. C. T., Josephson, K., & Szostak, J. W. (2012) · Journal of the American Chemical Society · doi:10.1021/ja301017y · Cited by 239
Hopkins, M. M., Martin, P. A., Nightingale, P., Kraft, A., & Mahdi, S. (2007) · Research Policy · doi:10.1016/j.respol.2007.02.013 · Cited by 234
Kiriiri, G. K., Njogu, P. M., & Mwangi, A. N. (2020) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-020-00047-9 · Cited by 227
“In the concept of drug discovery, genes have therefore been classified as disease genes, disease-modifying genes, and druggable genes [15].”
BackgroundBinding Site Detection and Druggability Index from First Principles
Seco, J., Luque, F. J., & Barril, X. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801385d · Cited by 239
Rossi Sebastiano, M., Doak, B. C., Backlund, M., Poongavanam, V., Over, B., Ermondi, G., Caron, G., Matsson, P., & Kihlberg, J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00347 · Cited by 234
Nie, Q., Du, X.-G., & Geng, M.-Y. (2011) · Acta Pharmacologica Sinica · doi:10.1038/aps.2011.14 · Cited by 234
The membrane protein universe: what's out there and why bother?
Von Heijne, G. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01792.x · Cited by 230
Rational Design of Small Molecule Inhibitors Targeting RhoA Subfamily Rho GTPases
Shang, X., Marchioni, F., Sipes, N., Evelyn, C. R., Jerabek-Willemsen, M., Duhr, S., Seibel, W., Wortman, M., & Zheng, Y. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.05.009 · Cited by 224
Wang, K., Saito, M., Bisikirska, B. C., Alvarez, M. J., Lim, W. K., Rajbhandari, P., Shen, Q., Nemenman, I., Basso, K., Margolin, A. A., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1563 · Cited by 237
“The ability to infer direct and upstream modulators of a desired TF's activity suggests that MINDy may provide highly specific pharmacological targets for the activation or repression of specific transcriptional programs, when modulators are restricted to druggable gene”
Structural insights into agonist-induced activation of G-protein-coupled receptors
Deupi, X., & Standfuss, J. (2011) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2011.06.002 · Cited by 234
Ocana, A., Pandiella, A., Privat, C., Bravo, I., Luengo-Oroz, M., Amir, E., & Gyorffy, B. (2025) · Biomarker Research · doi:10.1186/s40364-025-00758-2 · Cited by 187
“Those proteins that may not maintain a stable structure or lack a drug-binding pocket, are therefore considered as undruggable [22].”
A proteome-wide atlas of lysine-reactive chemistry
Abbasov, M. E., Kavanagh, M. E., Ichu, T.-A., Lazear, M. R., Tao, Y., Crowley, V. M., am Ende, C. W., Hacker, S. M., Ho, J., Dix, M. M., et al. (2021) · Nature Chemistry · doi:10.1038/s41557-021-00765-4 · Cited by 236
Multiple Independent Binding Sites for Small-Molecule Inhibitors on the Oncoprotein c-Myc
Hammoudeh, D. I., Follis, A. V., Prochownik, E. V., & Metallo, S. J. (2009) · Journal of the American Chemical Society · doi:10.1021/ja900616b · Cited by 229
Chemical proteomics and its application to drug discovery
Jeffery, D. A., & Bogyo, M. (2003) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(02)00010-1 · Cited by 233
Probing cell type–specific functions of Gi in vivo identifies GPCR regulators of insulin secretion
Regard, J. B., Kataoka, H., Cano, D. A., Camerer, E., Yin, L., Zheng, Y.-W., Scanlan, T. S., Hebrok, M., & Coughlin, S. R. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32994 · Cited by 233
“Introduction G protein–coupled receptors (GPCRs) regulate myriad physiological and disease processes and have been a rich source of targets for pharmaceuticals (1).”
BackgroundIUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels
Harmar, A. J., Hills, R. A., Rosser, E. M., Jones, M., Buneman, O. P., Dunbar, D. R., Greenhill, S. D., Hale, V. A., Sharman, J. L., Bonner, T. I., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn728 · Cited by 227
“voltage-gated-like ion channels (VGICs) and ligand-gated ion channels (LGICs) (1).”
BackgroundInfluential(1981) · PubMed · Cited by 235
Plasmodium Dihydroorotate Dehydrogenase: A Promising Target for Novel Anti-Malarial Chemotherapy
A. Phillips, M., & K. Rathod, P. (2010) · Infectious Disorders - Drug Targets · doi:10.2174/187152610791163336 · Cited by 229
“the target is “druggable) [32,33], that inhibitors of the target cause cell growth inhibition, and furthermore that selectivity can be achieved between the host and parasite.”
BackgroundThe Protein Interaction Landscape of the Human CMGC Kinase Group
Varjosalo, M., Keskitalo, S., Van Drogen, A., Nurkkala, H., Vichalkovski, A., Aebersold, R., & Gstaiger, M. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.03.027 · Cited by 227
Angiogenesis: from plants to blood vessels
Fan, T.-P., Yeh, J.-C., Leung, K. W., Yue, P. Y. K., & Wong, R. N. S. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.04.006 · Cited by 233
Structural Biology and Drug Discovery of Difficult Targets: The Limits of Ligandability
Surade, S., & Blundell, T. L. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.12.013 · Cited by 230
Melancon, B. J., Hopkins, C. R., Wood, M. R., Emmitte, K. A., Niswender, C. M., Christopoulos, A., Conn, P. J., & Lindsley, C. W. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201139r · Cited by 226
Cell-Based Assays for High-Throughput Screening
An, W. F., & Tolliday, N. (2010) · Molecular Biotechnology · doi:10.1007/s12033-010-9251-z · Cited by 220
Druggable protein–protein interactions – from hot spots to hot segments
London, N., Raveh, B., & Schueler-Furman, O. (2013) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2013.10.011 · Cited by 223
The Hippo Pathway in Heart Development, Regeneration, and Diseases
Zhou, Q., Li, L., Zhao, B., & Guan, K.-L. (2015) · Circulation Research · doi:10.1161/circresaha.116.303311 · Cited by 219
“127 GPCRs are the largest class of cell surface receptors encoded by the human genome and also the largest class of drug targets.(130,131) It is estimated that there are ≈200 GPCRs expressed in the heart.”
Molecular hybridization: a powerful tool for multitarget drug discovery
de Sena Murteira Pinheiro, P., Franco, L. S., Montagnoli, T. L., & Fraga, C. A. M. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2322990 · Cited by 204
“Seminal works by Hopkins and Groom (2002) [2], Barabási and Oltvai (2004) [3] and Hopkins (2008) [4] pioneered the fundamental principles of network pharmacology.”
Mechanistic enzymology in drug discovery: a fresh perspective
Holdgate, G. A., Meek, T. D., & Grimley, R. L. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.219 · Cited by 220
“Nature Reviews | Drug Discovery vi = v0 –([I]t–[E]t + Kiʹ) + ([I]t–[E]t+Kiʹ)(2)–4Kiʹ[E]t (2) 2[E]t”
Adversarial Threshold Neural Computer for Molecular de Novo Design
Putin, E., Asadulaev, A., Vanhaelen, Q., Ivanenkov, Y., Aladinskaya, A. V., Aliper, A., & Zhavoronkov, A. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b01137 · Cited by 211
Munoz, L., Ranaivo, H. R., Roy, S. M., Hu, W., Craft, J. M., McNamara, L. K., Chico, L. W., Van Eldik, L. J., & Watterson, D. M. (2007) · Journal of Neuroinflammation · doi:10.1186/1742-2094-4-21 · Cited by 224
“Protein kinases constitute an important class of druggable protein targets [76-78] and the multi-kinase inhibitors Gleevec (imatinib mesylate; Novartis), Nexavar (sorafenib; Bayer, Onyx), and Sutent (sunitinib malate; Pfizer) for treatment of various types of cancers are evidence of the potential for kinases to be the…”
The G protein-coupled receptor subset of the rat genome
Gloriam, D. E., Fredriksson, R., & Schiöth, H. B. (2007) · BMC Genomics · doi:10.1186/1471-2164-8-338 · Cited by 213
“It has been estimated that GPCRs represent between 30– 45% of the current drug targets [14,15].”
BackgroundFragment-based drug discovery using NMR spectroscopy
Harner, M. J., Frank, A. O., & Fesik, S. W. (2013) · Journal of Biomolecular NMR · doi:10.1007/s10858-013-9740-z · Cited by 213
“FBDD is frequently used to find lead molecules for proteins lacking deep or well-defined ligand binding pockets, so-called ‘‘undruggable’’ targets (Hopkins and Groom 2002).”
Co-evolving stability and conformational homogeneity of the human adenosine A2areceptor
Magnani, F., Shibata, Y., Serrano-Vega, M. J., & Tate, C. G. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804396105 · Cited by 214
“G protein-coupled receptors (GPCRs) represent one of the largest single families of integral membrane proteins in the human genome and bind multifarious ligands that mediate many physiological processes, which explains why GPCRs represent a major proportion of drug targets (1).”
BackgroundZhang, F., Wang, S., Yin, L., Yang, Y., Guan, Y., Wang, W., Xu, H., & Tao, N. (2015) · Analytical Chemistry · doi:10.1021/acs.analchem.5b02572 · Cited by 215
Progress in Structure Based Drug Design for G Protein-Coupled Receptors
Congreve, M., Langmead, C. J., Mason, J. S., & Marshall, F. H. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200371q · Cited by 215
Combining Drug and Gene Similarity Measures for Drug-Target Elucidation
Perlman, L., Gottlieb, A., Atias, N., Ruppin, E., & Sharan, R. (2011) · Journal of Computational Biology · doi:10.1089/cmb.2010.0213 · Cited by 218
“Figure taken from [30].”
Functionalised staple linkages for modulating the cellular activity of stapled peptides
Lau, Y. H., de Andrade, P., Quah, S.-T., Rossmann, M., Laraia, L., Sköld, N., Sum, T. J., Rowling, P. J. E., Joseph, T. L., Verma, C., et al. (2014) · Chem. Sci. · doi:10.1039/c4sc00045e · Cited by 214
Rescue of defective G protein–coupled receptor function in vivo by intermolecular cooperation
Rivero-Müller, A., Chou, Y.-Y., Ji, I., Lajic, S., Hanyaloglu, A. C., Jonas, K., Rahman, N., Ji, T. H., & Huhtaniemi, I. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906695106 · Cited by 210
Regulation of CaV2 calcium channels by G protein coupled receptors
Zamponi, G. W., & Currie, K. P. M. (2013) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2012.10.004 · Cited by 210
“brane proteins encoded by almost 800 human genes, and represent an important class of therapeutic targets [67,68].”
Target selection in drug discovery
Knowles, J., & Gromo, G. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd986 · Cited by 216
Strategies to Discover Unexpected Targets for Drugs Active at G Protein–Coupled Receptors
Allen, J. A., & Roth, B. L. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100553 · Cited by 216
Cardiac GPCRs: GPCR signaling in healthy and failing hearts
Salazar, N. C., Chen, J., & Rockman, H. A. (2007) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2007.02.010 · Cited by 205
An omics perspective on drug target discovery platforms
Paananen, J., & Fortino, V. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbz122 · Cited by 207
Cryptic binding sites on proteins: definition, detection, and druggability
Vajda, S., Beglov, D., Wakefield, A. E., Egbert, M., & Whitty, A. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.05.003 · Cited by 202
“First, many biologically relevant drug targets lack appropriately sized pockets in their unbound structures to support the strong binding of drug-sized ligands [7,11].”
Finding New Tricks For Old Drugs: An Efficient Route For Public-Sector Drug Discovery
O'Connor, K. A., & Roth, B. L. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1900 · Cited by 215
Discovery of multiple hidden allosteric sites by combining Markov state models and experiments
Bowman, G. R., Bolin, E. R., Hart, K. M., Maguire, B. C., & Marqusee, S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417811112 · Cited by 215
“Our approach can be applied to most soluble proteins, but could be of particular value for the large number of proteins that are currently considered undruggable because their active sites or binding interfaces are not considered viable drug targets (27).”
BackgroundFragment screening to predict druggability (ligandability) and lead discovery success
Edfeldt, F. N. B., Folmer, R. H. A., & Breeze, A. L. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.02.002 · Cited by 201
Borawski, J., Troke, P., Puyang, X., Gibaja, V., Zhao, S., Mickanin, C., Leighton-Davies, J., Wilson, C. J., Myer, V., CornellaTaracido, I., et al. (2009) · Journal of Virology · doi:10.1128/jvi.02418-08 · Cited by 202
“replicon cells as previously described (21, 23, 48).”
MethodUrwyler, S. (2011) · Pharmacological Reviews · doi:10.1124/pr.109.002501 · Cited by 207
Medicinal chemistry of target family-directed masterkeys
Müller, G. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02781-8 · Cited by 207
High-content single-cell drug screening with phosphospecific flow cytometry
Krutzik, P. O., Crane, J. M., Clutter, M. R., & Nolan, G. P. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.2007.59 · Cited by 207
“By comparing the inhibition profiles of the eight compounds simultaneously, we gained mechanistic insight into the susceptibility, or “druggability,” of multiple pathways and cell subtype”
BackgroundChoose and Use Your Chemical Probe Wisely to Explore Cancer Biology
Blagg, J., & Workman, P. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.005 · Cited by 203
The challenge of selecting protein kinase assays for lead discovery optimization
Ma, H., Deacon, S., & Horiuchi, K. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.6.607 · Cited by 197
“As such, protein kinases represent the largest ‘druggable’ gene family within the human genome [2] .”
BackgroundPockDrug-Server: a new web server for predicting pocket druggability on holo and apo proteins
Hussein, H. A., Borrel, A., Geneix, C., Petitjean, M., Regad, L., & Camproux, A.-C. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv462 · Cited by 196
“The ability of a protein to bind drug-like molecules, which are orally bioavailable, with a high affinity is often referred to as druggability, as first defined by Hopkins and Groom (1).”
BackgroundInfluentialI want a new drug: G-protein-coupled receptors in drug development
Schlyer, S., & Horuk, R. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.04.008 · Cited by 201
Dyall, J., Gross, R., Kindrachuk, J., Johnson, R. F., Olinger, G. G., Hensley, L. E., Frieman, M. B., & Jahrling, P. B. (2017) · Drugs · doi:10.1007/s40265-017-0830-1 · Cited by 199
“in cancer therapy, second only to the G protein-coupled receptors as therapeutic targets [83, 84].”
BackgroundProgress with covalent small-molecule kinase inhibitors
Zhao, Z., & Bourne, P. E. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.035 · Cited by 194
Investigating Cryptic Binding Sites by Molecular Dynamics Simulations
Kuzmanic, A., Bowman, G. R., Juarez-Jimenez, J., Michel, J., & Gervasio, F. L. (2020) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00613 · Cited by 200
sc-PDB: an Annotated Database of Druggable Binding Sites from the Protein Data Bank
Kellenberger, E., Muller, P., Schalon, C., Bret, G., Foata, N., & Rognan, D. (2006) · Journal of Chemical Information and Modeling · doi:10.1021/ci050372x · Cited by 201
Bauer, M. R., Ibrahim, T. M., Vogel, S. M., & Boeckler, F. M. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci400115b · Cited by 200
Application of text mining in the biomedical domain
Fleuren, W. W. M., & Alkema, W. (2015) · Methods · doi:10.1016/j.ymeth.2015.01.015 · Cited by 193
Emerging Strategies for Developing Next-Generation Protein Therapeutics for Cancer Treatment
Kintzing, J. R., Filsinger Interrante, M. V., & Cochran, J. R. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.10.005 · Cited by 191
“Conversely, small molecule drugs are typically nearly completely buried within a hydrophobic pocket of their protein binding partner to maximize hydrophobic contact and create a more stable complex [7].”
BackgroundComparative expression pathway analysis of human and canine mammary tumors
Uva, P., Aurisicchio, L., Watters, J., Loboda, A., Kulkarni, A., Castle, J., Palombo, F., Viti, V., Mesiti, G., Zappulli, V., et al. (2009) · BMC Genomics · doi:10.1186/1471-2164-10-135 · Cited by 193
“A total number of about 12,000 annotated gene sets were obtained from publicly available sources (Gene Ontology [83], KEGG [84], Interpro [85], Panther [86], oPOSSUM [87]), gene sets of relevance to cancer taken from published references [37,39,44,45,68,88-92]) and commercial sources (GeneGo (GeneGo Inc.”
BackgroundNgamcherdtrakul, W., Morry, J., Gu, S., Castro, D. J., Goodyear, S. M., Sangvanich, T., Reda, M. M., Lee, R., Mihelic, S. A., Beckman, B. L., et al. (2015) · Advanced Functional Materials · doi:10.1002/adfm.201404629 · Cited by 195
The Orphan G Protein–Coupled Receptor 3 Modulates Amyloid-Beta Peptide Generation in Neurons
Thathiah, A., Spittaels, K., Hoffmann, M., Staes, M., Cohen, A., Horré, K., Vanbrabant, M., Coun, F., Baekelandt, V., Delacourte, A., et al. (2009) · Science · doi:10.1126/science.1160649 · Cited by 196
A RaPID way to discover nonstandard macrocyclic peptide modulators of drug targets
Passioura, T., & Suga, H. (2017) · Chemical Communications · doi:10.1039/c6cc06951g · Cited by 193
Targeting Protein-Protein Interaction by Small Molecules
Jin, L., Wang, W., & Fang, G. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-140028 · Cited by 195
Targeting Bacterial Central Metabolism for Drug Development
Murima, P., McKinney, J. D., & Pethe, K. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.020 · Cited by 189
Data integration and genomic medicine
Louie, B., Mork, P., Martin-Sanchez, F., Halevy, A., & Tarczy-Hornoch, P. (2007) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2006.02.007 · Cited by 185
“There are many potential implications of genomic medicine for health care [3–5], including: individualized healthcare based on genetics [4], predictive methods for disease susceptibility [6], new drug targets for currently untreatable diseases [7], gene therapy [8], and genetic/molecular epidemiology which will aid in…”
Structural biology and drug discovery for protein–protein interactions
Jubb, H., Higueruelo, A. P., Winter, A., & Blundell, T. L. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.03.006 · Cited by 181
Stefan, E., Aquin, S., Berger, N., Landry, C. R., Nyfeler, B., Bouvier, M., & Michnick, S. W. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704257104 · Cited by 192
Cancer Genomics: Technology, Discovery, and Translation
Tran, B., Dancey, J. E., Kamel-Reid, S., McPherson, J. D., Bedard, P. L., Brown, A. M. K., Zhang, T., Shaw, P., Onetto, N., Stein, L., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.2316 · Cited by 188
Median Absolute Deviation to Improve Hit Selection for Genome-Scale RNAi Screens
Chung, N., Zhang, X. D., Kreamer, A., Locco, L., Kuan, P.-F., Bartz, S., Linsley, P. S., Ferrer, M., & Strulovici, B. (2008) · SLAS Discovery · doi:10.1177/1087057107312035 · Cited by 183
Modeling cancer metabolism on a genome scale
Yizhak, K., Chaneton, B., Gottlieb, E., & Ruppin, E. (2015) · Molecular Systems Biology · doi:10.15252/msb.20145307 · Cited by 183
“…should note that many relevant factors are actually out of the scope of such an endeavor, including the “druggability” of a predicted target, its cellular localization, its three-dimensional structure and its potential binding with known classes of inhibitors (Hopkins & Groom, 2002; Bunnage, 2011).”
Backgroundβ-Peptides as inhibitors of protein–protein interactions
Kritzer, J. A., Stephens, O. M., Guarracino, D. A., Reznik, S. K., & Schepartz, A. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.09.009 · Cited by 182
Could the gut microbiota reconcile the oral bioavailability conundrum of traditional herbs?
Chen, F., Wen, Q., Jiang, J., Li, H.-L., Tan, Y.-F., Li, Y.-H., & Zeng, N.-K. (2016) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2015.12.031 · Cited by 185
“Particularly, most of successful drugs achieve their activities by binding to and modifying the activity of a protein, with multiple consequences on various functions (Hopkins and Groom, 2002).”
BackgroundNext generation matrix metalloproteinase inhibitors — Novel strategies bring new prospects
Levin, M., Udi, Y., Solomonov, I., & Sagi, I. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2017.06.009 · Cited by 186
Blundell, T. L., Sibanda, B. L., Montalvão, R. W., Brewerton, S., Chelliah, V., Worth, C. L., Harmer, N. J., Davies, O., & Burke, D. (2006) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2005.1800 · Cited by 177
“Tractability of a target is based on the number of drug-like ligands for a target class, as well as knowledge of the binding sites of family members using protein structure information (Hopkins & Groom 2002).”
BackgroundAlphaFold heralds a data-driven revolution in biology and medicine
Thornton, J. M., Laskowski, R. A., & Borkakoti, N. (2021) · Nature Medicine · doi:10.1038/s41591-021-01533-0 · Cited by 185
Therapeutic Targets: Progress of Their Exploration and Investigation of Their Characteristics
Zheng, C. J., Han, L. Y., Yap, C. W., Ji, Z. L., Cao, Z. W., & Chen, Y. Z. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.2.4 · Cited by 185
“Investigations of the features of known therapeutic targets from earlier studies ( Hopkins and Groom , 2002 ; Hardy and Peet , 2004 ) and in the previous sections suggest that targets have certain common characteris - tics , which may be used as the basis for deriving rules for identification of…”
BackgroundInfluentialFunctional advantages of dynamic protein disorder
Berlow, R. B., Dyson, H. J., & Wright, P. E. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.06.003 · Cited by 183
“Most of the available pharmaceuticals have been designed to target specific classes of proteins with well-defined three-dimensional structures [105,106].”
An allosteric modulator to control endogenous G protein-coupled receptors with light
Pittolo, S., Gómez-Santacana, X., Eckelt, K., Rovira, X., Dalton, J., Goudet, C., Pin, J.-P., Llobet, A., Giraldo, J., Llebaria, A., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1612 · Cited by 177
Hot spots in protein–protein interfaces: Towards drug discovery
Cukuroglu, E., Engin, H. B., Gursoy, A., & Keskin, O. (2014) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2014.06.003 · Cited by 177
“Until very recently the druggable genome was believed to consist of only a limited number of protein families, such as G protein coupled receptors (GPCRs), serine/threonine and tyrosine protein kinases, zinc metallopeptidases, serine proteases, nuclear hormone receptors and phosphodiesterase (Hopkins and Groom, 2002).”
BackgroundFauman, E. B., Rai, B. K., & Huang, E. S. (2011) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2011.05.020 · Cited by 181
Expanding the Number of ‘Druggable’ Targets: Non‐Enzymes and Protein–Protein Interactions
Makley, L. N., & Gestwicki, J. E. (2013) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12066 · Cited by 176
“In a related concept, Hopkins and Groom presented the idea that the majority of drugs compete against endogenous small molecule regulators for binding sites on proteins (93).”
BackgroundSurface Plasmon Resonance Microscopy: From Single‐Molecule Sensing to Single‐Cell Imaging
Zhou, X., Yang, Y., Wang, S., & Liu, X. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.201908806 · Cited by 180
Erratum: Mechanistic enzymology in drug discovery: a fresh perspective
Holdgate, G. A., Meek, T. D., & Grimley, R. L. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.257 · Cited by 180
Xiao, J., Li, W., Zheng, X., Qi, L., Wang, H., Zhang, C., Wan, X., Zheng, Y., Zhong, R., Zhou, X., et al. (2020) · Immunity · doi:10.1016/j.immuni.2019.11.015 · Cited by 180
Bartz, S. R., Zhang, Z., Burchard, J., Imakura, M., Martin, M., Palmieri, A., Needham, R., Guo, J., Gordon, M., Chung, N., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.01229-06 · Cited by 177
“comprising the druggable genome (30), membrane proteins, enzymes, pathways”
BackgroundChen, X., Guan, N.-N., Sun, Y.-Z., Li, J.-Q., & Qu, J. (2018) · Briefings in Bioinformatics · doi:10.1093/bib/bby098 · Cited by 177
Metadata
- Authors
- Hopkins, A. L., & Groom, C. R.
- Affiliations
- Pfizer (United Kingdom) (GB)
- Corresponding author
- Groom, Colin R.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2002-09
- Volume
- 1
- Issue
- 9
- Pages
- 727-730
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2074370114
- Cited by
- 3,305
- References
- 16
- Citations by year
- 2026: 91 · 2025: 113 · 2024: 131 · 2023: 116 · 2022: 155 · 2021: 150 · 2020: 144 · 2019: 147 · 2018: 136 · 2017: 132 · 2016: 144 · 2015: 182 · 2014: 162 · 2013: 161 · 2012: 212
- FWCI
- 70.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Science, Research, and Medicine
- Keywords
- druggable genome, therapeutic target, molecular targets, target identification
- MeSH terms
- Biological Availability, Chemistry, Pharmaceutical, Humans, Molecular Biology, Pharmacokinetics, Genome, Human
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.